Post-print

The open access printed version of this paper can be found here:


**Attentional Bias Modification is associated with fMRI Response towards Negative Stimuli in Individuals with Residual Depression: A Randomized Controlled Trial**

E. Hilland¹,², N.I. Landrø¹,², C. J. Harmer¹,³, M. Browning⁴,⁵, L. A. Maglanoc⁶,⁷, & R. Jonassen¹,⁷

¹Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway. ²Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway. ³Psychopharmacology and Emotional Research Lab (PERL), University Department of Psychiatry, University of Oxford, Oxford, UK. ⁴Computational psychiatry laboratory, Department of Psychiatry, University of Oxford, Oxford, UK. ⁵Oxford health NHS Trust, Oxford, UK. ⁶NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Norway. ⁷Division of Psychiatry, Akerhus University Hospital, Oslo, Norway.

Corresponding authors: Eva Hilland & Nils Inge Landro

e-mail: eva.hilland@psykologi.uio.no; n.i.landro@psykologi.uio.no

University of Oslo, Department of Psychology

P.O Box 1094 Blindern 0317 Oslo, Norway
Abstract

Background

Attentional bias modification (ABM) may lead to more adaptive emotion perception and emotion regulation. Understanding the neural basis of these effects may lead to greater precision for future treatment development. Task-related functional magnetic resonance imaging (fMRI) following ABM training has so far not been investigated in depression. The main aim of this randomized controlled trial (RCT) was to explore differences in brain activity after ABM training in response to emotional stimuli.

Methods

A total of 134 previously depressed individuals who had been treated for depression and had various degrees of residual symptoms, were randomized into 14 days of active ABM- or a closely matched placebo training followed by an fMRI emotion regulation task. The training procedure was a classical dot-probe task with emotional face stimuli. In the active ABM condition the probes replaced the more positively valenced face of a given pair. As participants implicitly learned to predict the probe location this should induce a more positive attentional bias (AB). The placebo condition was identical, except the contingency of the probe which appeared equally often behind positive and negative stimuli. Depression symptoms and subjective ratings of perceived negativity during fMRI was examined between the training groups. Brain activation was explored within predefined regions of interest (ROI) and across the whole brain. Activation in areas associated with changes in AB and degree of depression was explored.
Results
The ABM group showed reduced activation within the amygdala and within the anterior cingulate cortex (ACC) when passively viewing negative images compared to the placebo group. No group differences were found within predefined ROI’s associated with emotion regulation strategies. Response within the temporal cortices was associated with degree of change in AB and with degree of depressive symptoms in ABM versus placebo.

Limitations
The findings should be replicated in other samples of depressed patients and in studies using fMRI designs that allow analyses of within-group variability from baseline to follow-up.

Conclusions
ABM training has an effect on brain function within circuitry associated with emotional appraisal and the generation of affective states.

Clinicaltrials.gov identifier: NCT02931487
Introduction

A number of effective treatments exist for major depressive disorder. However, following successful treatment relapse is common with 50-70% of patients relapsing within 5 years. Residual symptoms are among the strongest predictors for relapse in recurrent depression. Cognitive theories of depression posit that biased information processing for emotional stimuli plays a key role in development and relapse in depression. Despite mixed findings, clinically depressed subjects, as well as currently euthymic previously depressed subjects, have repeatedly been reported to orient their attention toward negative faces rather than neutral or positive faces. Attentional biases and deficits in cognitive control may interfere with emotion regulation and mood state. Negative cognitive biases in depression are thought to be facilitated by increased influence from subcortical emotion processing regions combined with attenuated top-down cognitive control. There is evidence for blunted responsiveness to positive stimuli and reward in depression. Concurrently, researchers have linked depression to dysregulated attentional processing of both positive and negative stimuli.

Computerized ABM procedures aim to implicitly retrain biased attentional patterns. Although there is debate about the true effect size of ABM in depression, some studies have reported reduced depressive symptoms after successful modification of AB. Antidepressant treatments have shown to dampen negative biases before clinical effects on mood are usually measurable, and these observations has led to a cognitive neuropsychological theory suggesting that modifying negative biases in emotional information processing may play a causal role in antidepressant treatment effects.
According to the theory, symptom improvement should consolidate over time. However, there is little empirical evidence of long-term effects of ABM. It has been suggested that attentional biases are an important component of explicit methods of emotion regulation. According to influential theories of emotion regulation, redirecting attention either towards or away from emotionally arousing aspects of a situation enables people to increase or decrease the intensity of emotions.

Psychological models of reappraisal suggest that that many of the same cognitive control processes that are used to regulate attention, memory and thoughts in general are also used in the cognitive regulation of emotion. Thus, it has been hypothesized that one way ABM may work could be by improving emotion regulation.

The neural basis of changes in AB, which is believed to be the mechanism of change behind symptom improvement after ABM training, has so far not been investigated. The functional neurobiology of emotion perception distinguishes between structures critical for appraisal, generation of affective states and emotion regulation. The amygdala and insular cortex are particularly important within a ventral system linked to the emotional significance of stimuli, and the production of affective states. The ventral ACC plays a main role in automatic regulation of emotional responses. A dorsal system includes the dorsal ACC and prefrontal regions and is argued to be involved in effortful regulation of affective states and subsequent behavior.

The neural effects of a single session of ABM in healthy individuals include lateral prefrontal cortex reactivity towards emotional stimuli, indicating moderation of the dorsal neurocircuitry in emotion perception. One resting state fMRI study in young women with sub-threshold depression found differences between ABM and placebo in...
measures of spontaneous fluctuations within the right anterior insula and right middle frontal gyrus, areas critical for emotion generation and automatic emotion regulation of emotional responses. In a study with clinically depressed participants differences in resting state connectivity between ABM and placebo was found within the middle frontal gyrus and dorsal ACC, a neural system important for cognitive control over emotions, along with changes in a network associated with sustained attention to visual information in the placebo group. Overall, these early results provide some evidence that ABM modifies function in emotional regulatory systems, although the small study sample sizes and variety of approaches used may underpin the absence of consistent effects across studies.

No study has investigated ABM-induced changes in emotion processing using fMRI in a large clinical sample after multiple training sessions. In this pre-registered clinical trial (NCT02931487) we used a sample of 134 participants previously treated for depression and with various degrees of residual symptoms. A main aim was to explore the neural effects of ABM within both ventral- and dorsal emotion perception circuitry during an emotion regulation task. The preregistered hypotheses were 1) The ABM group would show increased BOLD signal in prefrontal cortical regions, and 2) The ABM group would reveal decreased BOLD signal in the amygdala compared to placebo. Furthermore, we measured fMRI response within prefrontal and subcortical ROI’s in a well-established emotion regulation circuitry based on previous studies. Finally, we examined how changes in AB, the mechanism by which ABM is believed to work, and changes in symptoms differed between ABM- and placebo-treated groups.
Methods and materials

Participants and Screening procedures: Patients that had been treated for at least one previous episode of MDD were randomized into two treatment conditions with either a positive ABM- or a closely matched active placebo training condition. Block randomization (1:1) was performed at inclusion to ensure equal numbers of participants and similar characteristics for the two groups. Participants were invited to be part of the fMRI study immediately after training and preferably within one week after ABM training. The current clinical trial (NCT02931487) is an extension of a larger double-blinded randomized clinical trial (RCT)(NCT02658682) including 321 patients with a history of depression. A total of 136 eligible participants between 18-65 years old were enrolled for fMRI.

The main recruitment site was an outpatient clinic in the Department of Psychiatry, Diakonhjemmet Hospital in Oslo. Participants were also recruited from other clinical sites and via social media. Individuals diagnosed with a current major depressive episode, current- or former neurological disorder, psychosis, bipolar spectrum disorders, substance use disorders, attention deficit disorder, or head trauma were excluded via pre-screening. A history of an anxiety disorder was not exclusionary. Informed consent was obtained before enrolment. The procedure was approved by The Regional Ethical Committee for Medical and Health Research for Southern Norway (2014/217/REK sør-øst D). Inclusion criteria were individuals that had experienced more than one major depressive episode (life time) fulfilling the Mini International Neuropsychiatric Interview (M.I.N.I 6.0.0) A1a (depressed mood) and/or A2a (loss of interest or pleasure) criteria, more than 5 positive items on A3 and filling the A5 criterion (DSM 296.30-
To assess both clinically- and self-rated symptoms of depression, the Beck Depression Inventory (BDI-II)\textsuperscript{42} and Hamilton Rating Scale for Depression (HDRS)\textsuperscript{43} were administered. There was no upper or lower threshold for depression symptom scores. Raters were blind to the intervention.

**Attentional bias modification procedure:** The ABM task was a computerized visual dot-probe procedure developed by Browning and coworkers.\textsuperscript{21} A fixation cross was initially displayed followed by two images (the stimuli) presented concurrently on the top and bottom of the computer screen. Following stimulus onset, a probe (one or two dots) immediately appeared on the same location as one of the image stimuli and remained on the screen until the participant responded. Response was collected via a button press from one of two buttons. The types of stimuli were pictures of emotional faces. The face stimuli had three valences; positive (happy), neutral, or negative (angry and fearful) and were based on four databases, the Karolinska Directed Emotional Faces (KDEF)\textsuperscript{44}, NimStim\textsuperscript{45}, Matsumoto and Ekman's Japanese and Caucasian Facial Expressions of Emotion (JACFEE)\textsuperscript{46} and Ekman Pictures of Facial Affect \textsuperscript{47}. A single session of the task involved 96 trials with equal numbers of the three stimulus pair types. In addition, equal numbers of trials were randomly presented for 500- or 1000 ms before the probe was displayed. In each trial of the task, stimuli from two valences were displayed, in one of the following pairing types: positive-neutral, positive-negative, and negative-neutral. In the ABM condition, probes were located behind positive stimuli in 87\% of the trials (valid trials), as opposed to 13\% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when
completing the task. The neutral ABM placebo condition was otherwise identical, except the location of the probe, which was located behind the positive (valid trials) stimuli in 50% of the trials. Participants completed two sessions (192 trials) of ABM daily at home during the course of fourteen days (28 sessions in total) on identical notebook computers (14" HP EliteBook 840, 1600x900, 8GB, Intel Core i5-4310U), which were set up and used exclusively for ABM-training. The duration for each training session was ~5 minutes. Compliance was ensured by a calendar system and daily reminders on sms. Compliance rates for the training procedure (percentage complete sessions) were calculated from the computers’ log files, and were 82.32%.

**MRI Scan acquisition:** Scanning was conducted on a 3T Philips Ingenia whole-body scanner, with a 32 channel Philips SENSE head coil (Philips Medical Systems). Functional images were obtained with a single-shot T2* weighted echo planar imaging sequence (repetition time (TR): 2000 ms; slice echo time (TE): 30 ms; field of view (FOV): 240x240x117; imaging matrix: 80x80; flip angle 90°, 39 axial slices, interleaved at 3 mm thickness, no gap, voxel size 3x3x3 mm). The scanning session consisted of 340 volumes, synchronized to the onset of the experiment. Slice orientation was adjusted to the line running from the anterior to posterior commissure. A T1-weighted anatomical image with a voxel size of 1x1x1 mm was recorded for registration of the functional images (TR: 8.5 ms; TE: 2.3 ms; FOV: 256x256x184; flip angle: 7°;184 sagittal slices).

**fMRI Experimental procedure:** The study used a modified emotion regulation experiment. Participants were scanned as they were viewing sequences of negative and neutral images while carrying out instructions either to down-regulate their emotional
responses using a reappraisal strategy, or to simply allow themselves to attend to the pictures without trying to influence their emotional reactions. After each image the participants provided a rating of the intensity of their emotional state using a visual analogue scale (VAS) ranging from neutral to negative. Stimuli were selected from the International Affective Picture System \(^4\) and the Emotional Picture Set.\(^4\) Negative and neutral pictures were counterbalanced concerning their normative valence and arousal ratings (see Supplemental information for more detail). Each trial started with a fixation cross followed by a written instruction, (“Attend” or “Regulate”). The instruction was presented for 2000 ms. A negative or neutral image was presented for 6000 ms, followed by a rating screen time-locked to 6000 ms. Between stimuli there was a temporal jitter randomized from 2000-8000 ms (mean ISI; 3,700 ms) to optimize statistical efficiency in the event related design.\(^5\) The task consisted of blocks of 18 trials with a 20 second null-trial between the two blocks. The procedure was completed in two independent runs during the scanning session, 72 trials in total. In each block 12 items were neutral and 24 items were negative, giving three counterbalanced experimental conditions; AttendNeutral, AttendNegative, RegulateNegative. The stimulus-order in each block was interspersed pseudo-randomly from 12 unique lists. The total duration of one single functional scanning run was ~11 minutes, and total scan time~22 minutes. Stimuli were presented using E-Prime 2.0 software (Psychology Software Tools). An MRI compatible monitor was placed at the end of the scanner behind the participants’ head. Participants watched the monitor using a mirror placed at the head coil. Responses were collected with a response grip with two response buttons. Physiological data (heart and respiration curves) were recorded at 1000 Hz using a clinical monitoring unit digitized together with scanner pulses.
Training and instruction procedures: A written protocol with detailed instructions was used to introduce the emotion regulation experiment. The protocol was dictated for each participant by the researcher outside the MRI-scanner in order to standardize the verbal instructions. The fMRI experiment had three in-scanner exercise trials before scan start in order to make participants familiar with the instructions, timing, response buttons and VAS scale. The training procedure was repeated before the second run of the experiment.

Symptom change and subjective ratings of negativity: Changes in self-rated and clinician rated symptoms were analyzed in PASW 25.0 (IBM) using a repeated measures ANOVA with intervention (ABM versus placebo training) as a fixed factor. Symptoms at baseline and at two weeks follow-up (time) were the dependent variable. To investigate self-reported emotional reactivity (VAS scores) during fMRI a factor based on the three experimental conditions AttendNeutral, AttendNegative, RegulateNegative was added as factor and analyzed in a repeated measures ANOVA.

fMRI analyses: Whole brain analysis used the AttendNegative > AttendNeutral contrast to tests whether ABM influences overall brain activity in response passive viewing of emotional stimuli. Clinician-rated (HRSD) symptoms at baseline was demeaned (subtracting the mean from the individual value) and used as covariate. Spatial smoothing FWHM was set to 5 mm. Featquery was used for FEAT result interrogation. Mean local percent signal change was extracted to explore individual distribution within significant clusters from FEAT. Interaction analysis was performed in order to test
whether areas within the brain respond differently in ABM versus placebo in relation to AB and symptom change.

The ROI analysis was performed using a small volume correction (SVC) method with a priori volumes based on coordinates from a recent meta-analysis on neuroimaging and reappraisal. The meta-analysis by Buhle et al \(^{51}\) is comprised of 48 neuroimaging studies of reappraisal where the majority of studies involved downregulation of negative affect, and reported seven clusters related to emotion regulation consistently found within prefrontal cognitive control areas when contrasted to passive viewing of negative images. The clusters were situated in left and right middle frontal gyrus, right inferior frontal gyrus, right medial frontal gyrus, left and right superior temporal lobe, and left middle temporal gyrus (See Supplemental). The bilateral amygdala, but no other brain regions were reported for the opposite contrast comparing negative viewing to emotion regulation. Brain activation derived from passive viewing of negative images as compared to passive viewing of neutral images was not included in the results from the meta-analysis.\(^{51}\)

Binary spheres with a 5 mm radius based on MNI coordinates of peak voxels were used for the predefined regions. Two single masks were created for the emotion regulation contrast (RegulateNegative > AttendNegative, AttendNegative > RegulateNegative). The seven cortical spheres and the two subcortical spheres respectively were combined into two single binary ROI’s. Z- threshold was set to 2.3 and cluster p-threshold was .05. Mean local percent signal change was extracted from the two ROI’s to explore individual
distribution within significant clusters from FEAT. Again, clinician-rated (HRSD) symptoms at baseline was demeaned and used as covariate also in the ROI analysis.

**fMRI data preprocessing and noise reduction:** The FMRIB Software Library version (FSL version 6.00) ([www.fmrib.ox.ac.uk/fsl](http://www.fmrib.ox.ac.uk/fsl)) was used to pre-process and analyze fMRI data. FMRI data processing was carried out using FEAT (FMRI Expert Analysis Tool) Version 6.00, part of FSL (FMRIB’s Software Library, [www.fmrib.ox.ac.uk/fsl](http://www.fmrib.ox.ac.uk/fsl)). In conjunction with FEAT FSL-PNM, 34 EVs were applied to regress out physiological noise from pulse and respiration. Registration to high resolution structural and/or standard space images was carried out using FLIRT. Registration from high resolution structural to standard space was then further refined using FNIRT nonlinear registration. All registrations were manually inspected to ensure proper alignment.

Time-series statistical analysis was carried out using FILM with local autocorrelation correction. Linear registration was conducted with 12 degrees of freedom (DOF). Z (Gaussianised T/F) statistic images were thresholded using clusters determined by Z>2.3 and a (corrected) cluster significance threshold of P=0.05. Two participants were excluded from the analyses due to signal loss caused by a technical problem with the head coil. Time series from each subjects’ two first level runs were combined using an intermediate fixed effect model in FEAT before submission to second level analysis. A total of 134 participants, 64 from the ABM group and 70 from the placebo group were included in the intermediate - and the higher level FEAT analysis at group level. Non-parametric testing using FSL randomise with threshold-free cluster enhancement and 5000 permutations was conducted as an alternative to FEAT with a cluster defining threshold.
## Results

### Sample characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=70)</th>
<th>ABM (n=64)</th>
<th>Value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>39.65 (13.54)</td>
<td>39.09 (12.80)</td>
<td>.061</td>
<td>.805</td>
</tr>
<tr>
<td>Gender (females)</td>
<td>44</td>
<td>47</td>
<td>1.717</td>
<td>.201</td>
</tr>
<tr>
<td>Education Level (ISCED)</td>
<td>5.92 (1.20)</td>
<td>5.85 (1.27)</td>
<td>.113</td>
<td>.737</td>
</tr>
<tr>
<td>Medication (SSRI)</td>
<td>23</td>
<td>22</td>
<td>.035</td>
<td>.857</td>
</tr>
<tr>
<td>Number of previous MDE</td>
<td>4.48 (5.30)</td>
<td>4.79 (7.56)</td>
<td>.077</td>
<td>.782</td>
</tr>
<tr>
<td>Days between ABM and fMRI</td>
<td>6.94 (8.70)</td>
<td>6.65 (7.19)</td>
<td>.041</td>
<td>.840</td>
</tr>
</tbody>
</table>

### Baseline symptoms:

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>ABM</th>
<th>Value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRSD</td>
<td>7.53 (4.69)</td>
<td>9.56 (6.38)</td>
<td>4.469</td>
<td>.036</td>
</tr>
<tr>
<td>BDI-II</td>
<td>12.09 (8.66)</td>
<td>17.12 (11.62)</td>
<td>8.187</td>
<td>.005</td>
</tr>
</tbody>
</table>

Table 1 shows means, standard deviations for continuous and dichotomous values respectively. MDE=Major Depressive Episodes according to M.I.N.I. SSRI= any current usage of an antidepressant belonging to the Selective Serotonin Reuptake Inhibitors. ISCED= International Standard Classification of Education. P-values from Pearson Chi-Square test is presented for dichotomous variables.

**Symptom change after ABM:** There was a statistically significant group*time interaction for rater-evaluated depression as measured by the change in HRSD. Follow up comparisons for this significant interaction revealed lower symptoms of depression in the ABM group [F (1,132) = 4.277, $\eta^2 = .03$, p = .041]. The means and standard deviations at baseline in ABM was (9.56 (6.38)) and placebo (7.53 (4.69)) and changed to (7.93 (5.90)) and (7.77 (5.76)) at two weeks follow-up. No statistically significant effect was found for self-reported symptoms as measured by the BDI-II [F (1,132) = 2.048, p = .155]. The means and standard deviations at baseline in ABM was
(17.12 (11.62)) and placebo (12.09 (8.66)) and changed to (13.25 (12.04)) and (9.82 (8.72)) at two weeks follow-up. There was a general symptom improvement in both the ABM and placebo group as measured by the BDI-II from baseline to post training [F (1,132) = 29.775, \(\eta^2 = .18, p < .001\)]. This is in accordance with the results from the sample in which this smaller cohort of subjects is drawn (41).

**Subjective ratings of perceived negativity:** We found a statistically significant difference between self-reported emotional reactivity measured by VAS scores during the fMRI experiment between task conditions. The repeated measures ANOVA showed that mean VAS scores were lowest when viewing neutral images (M=8.2(7.8)) followed by when patients were encouraged to regulate negative experience towards negative images (M=40.8 (16.9)), and highest for the passive viewing of negative images (62.0(15.3)) [F = (1,133) = .074, \(\eta^2 = .93, p < .001\)]. A post hoc test showed that the differences between the passive and regulate viewing conditions for negative stimuli was large and statistically significant F (1,133) = 202.81, \(\eta^2 = .60, p < .001\). VAS ratings did not differ between ABM and placebo [F = (1,133) = .993, p < .646].

**Post-treatment differences between ABM- and placebo-treated groups from whole brain analyses:** The RegulateNegative>AttendNegative and AttendNegative>RegulateNegative contrasts revealed no group difference. AttendNegative > AttendNeutral revealed greater activation in the placebo-treated group in a cluster within the pregenual ACC, the paracingulate – and the medial cortex bilaterally, extending to the right frontal orbital cortex and the frontal pole compared to
ABM. The peak activation for this cluster was found in the left frontal medial cortex (MNI coordinates x y z = -16 36 -10, Z=3.86, p=.001) (Figure 1.)

Figure 1 shows cluster activation (Z>2.3) for Placebo over ABM for the AttendNegative>AttendNeutral contrast (left), together with distribution of individual percentage signal changes over significant clusters (right).

Post-treatment difference between ABM- and placebo-treated groups within predefined ROI’s: Analyses masked across predefined emotion regulation circuitry revealed more activation in the placebo-treated group compared to ABM within the right- (MNI x y z = -18 -6 -20, size=8, Z=2.89, p=.032) and left amygdala (MNI x y z = 28 0 -16, size= 3, Z = 2.55, p = .040) for the passive viewing contrast (AttendNegative > AttendNeutral) (Figure 2.).
Figure 2 shows amygdala activation for the AttendNegative>AttendNeutral contrast. **Left:** Red voxels represent mean amygdala activation across placebo- and ABM training groups. Yellow voxels are superimposed and represent peak voxels where the placebo group had more activation compared to the ABM-group. **Right:** Distribution of individual percentage signal changes over significant clusters (right).

No differences between ABM and placebo were found for the emotion regulation contrasts. Across both groups the regulate contrast (RegulateNegative > AttendNegative) revealed activation within two ROI’s in the left inferior frontal gyrus (MNI x y z = -30 -2 -54, size=75, Z=10.5, p=.017) and right middle frontal gyrus (MNI x y z = 60 26 6, size=29, Z=5.48, p=.048). The opposite contrast (AttendNegative > RegulateNegative) revealed increased bilateral amygdala activation in both the ABM- and placebo group. The largest cluster was found within the left amygdala (MNI x y z = -18 0 -14, size=75, Z=7.93; p=.006) and a smaller cluster was found within the right amygdala (MNI x y z = 26, -2, -16, size=13, Z=4.05, p=.026) (supplemental Figure1).
Non-parametric testing using randomise did not reveal statistically significant cluster activation for whole brain or predefined ROI’s.

*Interaction with degree of attentional biases and symptom change:*

Two distinct clusters were associated with the interaction between the passive viewing of negative images (AttendNegative > AttendNeutral), the intervention and degree of AB change (MNI x y z = 54 -24 8, size=1061; Z=4.05, p<.001) and (MNI x y z =-50 0 10, size=547, Z=3.44; p<.020). Degree of changes in AB was associated with lower percentage signal change in the ABM group, and a higher percentage signal change in the placebo group. (Figure 3).
Figure 3 shows areas activated in association to the interaction between AB and the intervention for AttendNegative>AttendNeutral (left). The scatter plot (right) shows the regression lines and individual distribution in the ABM and the placebo condition.

An interaction between passive viewing (AttendNegative > AttendNeutral), the intervention, and degree of symptom change (HRSD) were found within the right planum temporale and insular cortex (MNI x y z = 50 -10 18, size=872; Z=5.28, p<.001). Degree of symptom change was associated with lower percentage signal change in the ABM group, and a higher percent signal change in the placebo group. (Figure 4.)
Figure 4 shows areas activated in association to the interaction between HRSD and the intervention for AttendNegative>AttendNeutral (left). The scatter plot (right) shows the regression lines and individual distribution in the ABM and the placebo condition.

Sensitivity analysis and non-parametric testing: Clusters thresholding determined by $Z > 3.1$ and a (corrected) cluster significance threshold of $P = .001$ did not reveal statistically significant cluster activation in whole brain analysis or SCV’s. None of the reported results survived non-parametric testing using randomize (5000 permutations, threshold free cluster enhancement, TFCE).
Discussion

Our results revealed differences in brain activity between ABM- and placebo training groups related to passive viewing of negative stimuli within areas consistently associated with emotional appraisal and the generation of affective states, areas within a circuitry known to be altered in depression.\textsuperscript{4,35,37} The placebo group showed more pronounced activation within the amygdala, in midline structures, and in the pregenual ACC. We did not find group differences related to explicit emotion regulation. Analysis of the mechanism of change showed that degree of changes in AB was linearly linked to activity in the insular cortex bilaterally. Symptom improvement after ABM was linearly associated with activation in the right insular cortex, areas involved in the generation of affective states.\textsuperscript{35}

Analyses within predefined areas associated with effortful emotion regulation revealed activation within the left inferior frontal gyrus and right middle frontal gyrus across groups.\textsuperscript{51} The amygdala was also more activated during passive viewing versus explicit regulation of negative stimuli, but did not differ between the ABM and placebo group. In line with these results, we found no differences between ABM and placebo training as measured by subjective ratings (VAS) of perceived negativity. This is consistent with the primary outcomes from the clinical trial that found an ABM effect restricted to blinded clinician-rated, but not self-rated symptoms.\textsuperscript{62} Together, the results may imply that the early effects of ABM are restricted to changes in emotion generation and appraisal, as opposed to more conscious forms of emotion regulation linked to the dorsal system.
A considerable number of meta-analyses using functional connectivity in depression have shown altered activity in areas that distinguished ABM and placebo in the current study, including the insula and ACC\textsuperscript{63-65}66. Midline brain structures including the pregenual ACC has been linked to self-referential processing\textsuperscript{68}, hopelessness\textsuperscript{69}, anhedonia\textsuperscript{70} and impaired emotion processing\textsuperscript{71} and is identified in studies of functional connectivity in depression. Notably, the ACC and insula are together with the amygdala core areas of the salience network, which determines the significance of external stimuli. The salience network has been hypothesized to play a role in switching between task positive- and negative networks\textsuperscript{72,73} and may well play a role in symptom improvement after ABM as found in this study.

The insula and the amygdala are among core brain areas that respond preferentially to negative stimuli in healthy individuals, and activation in the insula and ACC has repeatedly been reported across a range of experiments using emotional tasks with cognitive demand and mental imagery\textsuperscript{74,75}. Neural responses to negative stimuli within the amygdala, insula and ACC are found to be more pronounced in depressed patients versus healthy controls\textsuperscript{76}. Ma\textsuperscript{77} describes an emotional circuit including the insula, bilateral amygdala and ACC affected by antidepressant medication by decreasing activity towards negative- and increasing activity towards positive stimuli. Antidepressants have been hypothesized to work by remediating negative affective biases, i.e. targeting the same mechanism as when applying an ABM procedure\textsuperscript{26,78,79}. Similarly, the moderation of awareness towards negative stimuli via ABM (the hypothesized mechanism of change) may alter automatic emotional vigilance and arousal towards negative stimuli. This moderation may lead to altered parasympathetic responses via circuitry involving the
amygdala and ACC. The translation of these changes into improved subjective mood may take some time as the individual learns to respond to this new and more positive social and emotional perspective of the world. However, neural correlates of early changes in the processing of emotional stimuli might be a marker of a process leading to symptom improvement. This model is consistent with cognitive theories of depression which the ABM procedure builds on. Accordingly, studies on cognitive behavioral therapy (CBT) show that pregenual ACC is positively correlated with the degree of symptom improvement. Moreover, given that the pregenual ACC is believed to play an important role in downregulation of limbic hyperreactivity the group difference found in this study may reflect more adaptive emotion processing after ABM.

Worldwide, there is a pressing demand for evidence-based treatments in mental health. It has been argued that psychotherapy research does not provide explanations for how or why even the most commonly used interventions produce change. In a recent statement from the Lancet Psychiatry’s Commission on treatments research in tomorrow’s science the authors argue that there is an acute need to improve treatment and thus clinical trials should focus not only on efficacy, but also on identification of the underlying mechanisms through which treatments operate. The current study is addressing such mechanisms by targeting changes in AB, which is believed to be the mechanism, that translate into symptom improvement after ABM.

The current study is based on an RCT with a larger sample of patients that found an ABM effect on clinician-rated symptoms. It uses a well validated emotion perception task and follows a stringent pre-registered research protocol which represents a
strength. This study exploits the link between a psychological mechanism, clinical measures and underlying brain function measured by fMRI, thus the results should have translational potential. The current trial is the largest study that has investigated changes in emotion processing using fMRI after ABM training.
Limitations

A key limitation related to the research design is that fMRI assessment after ABM does not allow statistical modeling of within-individual variance from baseline to follow-up. There is an unexpected difference in symptom degrees at baseline that could be associated with group differences in brain activation. We sought to address this possible confound by including symptom degree as a covariate in the fMRI analyses. The higher baseline symptom scores in the ABM group may still represent a higher potential for change. The sample consists of patients with previous depression and various degrees of residual symptoms, and needs to be replicated in studies with other patient groups. Brain activation related to ABM may also be conditionally mediated by multiple biological- and environmental factors outside the scope of this study. Future studies should also consider experimental designs that include passive viewing- and up-regulation for positive images in order to match for potential process and arousal effects. More precise insight regarding stimulus characteristics such as arousal and valence may help validate future ABM procedures. The risk of false positive findings should be reduced by a relative large sample size, correction for physiological artifacts, and a study design where only voxel activation over two individual runs was submitted to group level analysis. However, the results did not survive non-parametric testing or stricter thresholding as suggested by Eklund et al \textsuperscript{91}, but see also \textsuperscript{92,93}. Further replication of the reported findings is warranted.
Conclusion

This study demonstrates ABM-associated differences in brain circuitry linked to passive viewing, but not conscious regulation of emotional stimuli and represents the first experimental evidence of an ABM effect using task-based fMRI.
Acknowledgements: We want to thank our fMRI research assistant Dani Beck. Further, we thank Diakonhjemmet Hospital, Division of Psychiatry, for help and support during the recruiting period and the Intervention Center, OUS for radiological assistance in MRI protocols, data acquisitions and screening for unexpected neuropathological findings. We thank Tor Endestad for establishing invaluable infrastructure for MRI research in our department.

We also thank our external recruitment sites; Unicare, Coperiosenteret AS, Torgny Syrstad, MD, Synergi Helse AS and Lovisenberg Hospital. The project is supported by the South-Eastern Norway Regional Health Authority, grant number: 2015052 (to NIL), Research Council Norway, grant number: 229135 (to NIL) and Department of Psychology, University of Oslo.

Conflicts of interest: CJH has received consultancy fees form Johnson and Johnson Inc, P1 vital and Lundbeck. MB hold a part time position at P1 vital Ltd and owns shares in P1 vital products Ltd. MB has received travel expenses from Lundbeck and has acted as a consultant for J&J, and NIL has received consultancy fees and travel expenses from Lundbeck. EH, LM and RJ reports no biomedical financial interests or potential conflicts of interest.
References


